Skip to content
Citation only via OpenAlex

Ranibizumab for age-related macular degeneration

Dilsher S. Dhoot, Peter K. Kaiser

Expert Opinion on Biological Therapy · 2012 · ▲ 54 citations

Abstract

INTRODUCTION: Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years in the developed world. The wet form of AMD is responsible for the majority of severe vision loss. VEGF-A is a key component in the development of wet AMD. Ranibizumab is an anti-VEGF agent that has established itself as the gold standard in the treatment of neovascular AMD. Herein, we review the pharmacology, pharmacokinetics, efficacy and safety of ranibizumab. AREAS COVERED: Since its approval in 2006, ranibizumab has revolutionized the treatment of wet AMD. In two pivotal Phase III trials, MARINA and ANCHOR, ranibizumab (0.5 mg) prevented moderate visual loss in 90 and 96% of patients, respectively, and improved vision by 15 letters or more in 33 and 40% of patients, respectively. Fixed monthly dosing regimens were compared with quarterly dosing regimens in PIER and EXCITE studies and support the superiority of fixed monthly dosing. The CATT trial revealed that bevacizumab was not inferior to ranibizumab when dosed monthly. As-needed treatment regimens of ranibizumab were also found to be non-inferior to monthly ranibizumab after 1 year of follow-up. EXPERT OPINION: Ranibizumab has positively altered the treatment of wet AMD and offers hope for millions of patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1517/14712598.2012.660523
Canonical
link ↗
Fetched
2026-10-19 MST

Cite this

APA
Dhoot, D.S., &amp; Kaiser, P.K. (2012). Ranibizumab for age-related macular degeneration. <em>Expert Opinion on Biological Therapy</em>. https://doi.org/10.1517/14712598.2012.660523
Vancouver
Dhoot DS, Kaiser PK. Ranibizumab for age-related macular degeneration. Expert Opinion on Biological Therapy. 2012. doi:10.1517/14712598.2012.660523.
BibTeX
@article{dilsher2012Ranibi, title = {Ranibizumab for age-related macular degeneration}, author = {Dilsher S. Dhoot and Peter K. Kaiser}, journal = {Expert Opinion on Biological Therapy}, year = {2012}, doi = {10.1517/14712598.2012.660523}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings